Abstract
The clinical challenge for treating HER2 (human epidermal growth factor receptor 2)-low breast cancer is the paucity of actionable drug targets. However, the discovery of immune checkpoint inhibitors has made immunotherapy an emerging new treatment modality for breast cancer. Moreover, several chemotherapeutic agents are known to induce immunogenic cell death by activating the immune system. Therefore, we hypothesized that modulating the tumour microenvironment using trastuzumab and or trastuzumab deruxtecan (T-Dxd) in breast organoids co-cultured with T-cells might enhance the response to immunotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
